Clinical trial
Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer
NCT00009958 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00009958 |
|---|---|
| Title | Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer |
| Official title | A Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM (B7.1/ICAM/LFA-3) Alone, and in Combination With Vaccinia-CEA(6D)-TRICOM, and the Role of GM-CSF, in Patients With CEA Expressing Carcinomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Other |
| Interventions | recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, sargramostim, laboratory biomarker analysis |
| Enrollment | 42 |
| Start date | Nov 1, 2000 |
| Primary completion | Apr 1, 2010 |
| First posted | Feb 3, 2004 |
| Last update posted | May 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: